

Meningococcal Vaccine Market by Serogroup (MenACWY, MenB/BC, MenC, MenAC, and MenA), Vaccine Type (Conjugate, Polysaccharide, and Subcapsular), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2018–2026

<https://marketpublishers.com/r/MEB902A68453EN.html>

Date: April 2020

Pages: 197

Price: US\$ 4,296.00 (Single User License)

ID: MEB902A68453EN

Abstracts

The global meningococcal vaccine market was valued at \$1,935.5 million in 2018, and is projected to reach \$4,192.5 million by 2026, registering a CAGR of 9.5% from 2019 to 2026. Invasive meningococcal disease (IMD) is a bacterial infection caused by a gram-negative coccus, *Neisseria meningitidis*, which includes spectrum of infections including meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. Although meningococcal disease is rare but is associated with high fatality of up to 50% if left untreated and often results in serious complications thereafter. Meningococcal meningitis results in infection of the lining of the brain and spinal cord and also has a potential to cause large epidemics as well as endemics. The disease is generally transmitted through direct contact with droplets of respiratory or throat secretions from patients or asymptomatic carriers. Various serotypes of *N. meningitidis* are included in 12 serogroups of which only 5 serogroups including A, B, C, W, and Y are responsible for the majority of disease worldwide. However, circulation of these serogroups is highly unpredictable and varies over time across age groups and geographies. Vaccines for each of these serogroups are available in the market.

It is estimated that the meningococcal vaccine market is expected to experience significant market growth during the forecast period as there has been an increase in adoption in several countries across the globe in their national immunization programs. In addition, surge in meningococcal outbreaks in several countries has led to upsurge in

demand for meningococcal vaccines, which further facilitate the growth of the market. However, stringent government regulations for the approval of new vaccines and recall of several products due to contamination are expected to impede the market growth. In contrast, high population base in emerging markets and global increase in healthcare spending provides significant growth opportunities for the meningococcal vaccine market.

The global meningococcal vaccine market is segmented on the basis of serogroup, vaccine type, end user, and region. The serogroups covered in the study include MenACWY, MenB/BC, MenC, MenAC, and MenA. Depending on vaccine type, the market is classified into conjugate, polysaccharide, and subcapsular. According to end user, the market is segmented into pediatric, adults, and travelers. By region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (the UK, Germany, France, the Netherlands, Spain, and rest of Europe), Asia-Pacific (China, Australia, and rest of Asia-Pacific), and LAMEA (Latin America, the Middle East, and Africa).

KEY BENEFITS FOR STAKEHOLDERS

The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.

It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.

A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.

The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.

KEY MARKET SEGMENTS

By Vaccine Serotype

MenACWY

MenB & MenBC

MenC

MenA

MenAC

By Vaccine Type

Conjugate

Polysaccharide

Subcapsular

By End User

Pediatric

Adult

Travelers

By Region

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

the Netherlands

Spain

Rest of Europe

Asia Pacific

China

Australia

Rest of Asia-Pacific

LAMEA

Latin America

Middle-East

Africa

LIST OF KEY PLAYERS PROFILED IN THE REPORT

Bio-Manguinhos

Bio-Med Pvt. Limited

Chongqing Zhifei Biological Products Co., Ltd.

GlaxoSmithKline Plc

Hualan Biological Engineering Inc.

Incepta Pharmaceuticals Ltd.

Pfizer INC

Sanofi S.A.

Serum Institute of India Pvt. Ltd

Walvax Biotechnology Co., Ltd.

Contents

CHAPTER 1:INTRODUCTION

- 1.1.Report description
- 1.2.Key benefits for stakeholders
- 1.3.Key market segments
 - 1.3.1.List of key players profiled in the report
- 1.4.Research methodology
 - 1.4.1.Secondary research
 - 1.4.2.Primary research
 - 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

- 2.1.Key findings of the study
 - 2.1.1.CXO perspective

CHAPTER 3:MARKET OVERVIEW

- 3.1.Market definition and scope
- 3.2.Key findings
 - 3.2.1.Top investment pockets
- 3.3.Porter's five forces analysis
 - 3.3.1.Bargaining power of buyers
 - 3.3.2.Bargaining power of suppliers
 - 3.3.3.Threat of new entrants
 - 3.3.4.Threat of substitutes
 - 3.3.5.Intensity of competitive rivalry
 - 3.3.6.Market share analysis, 2018
- 3.4.Market dynamics
 - 3.4.1.Drivers
 - 3.4.1.1.Increase in outbreaks of meningococcal disease
 - 3.4.1.2.Surge in immunization programs across the globe
 - 3.4.1.3.Increase in research and development for vaccine technology
 - 3.4.2.Restraint
 - 3.4.2.1.Longer timelines required for vaccine production
 - 3.4.2.2.High costs associated with the development of vaccines
 - 3.4.3.Opportunities

- 3.4.3.1.Growth opportunities in the emerging markets
- 3.4.3.2.Increase in healthcare spending
- 3.4.3.3.Increase in research and development for meningococcal vaccines
- 3.4.4.Impact analysis

CHAPTER 4: MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE

4.1.Overview

- 4.1.1.Market size and forecast

4.2.MenACYW Vaccine

- 4.2.1.Key market trends, growth factors, and opportunities
- 4.2.2.Market size and forecast, by region
- 4.2.3.Market analysis, by country

4.3.MenB/BC Vaccine

- 4.3.1.Key market trends, growth factors, and opportunities
- 4.3.2.Market size and forecast, by region
- 4.3.3.Market analysis, by country

4.4.MenC Vaccine

- 4.4.1.Key market trends, growth factors, and opportunities
- 4.4.2.Market size and forecast, by region
- 4.4.3.Market analysis, by country

4.5.MenA Vaccine

- 4.5.1.Key market trends, growth factors, and opportunities
- 4.5.2.Market size and forecast, by region
- 4.5.3.Market analysis, by country

4.6.MenAC Vaccine

- 4.6.1.Key market trends, growth factors, and opportunities
- 4.6.2.Market size and forecast, by region
- 4.6.3.Market analysis, by country

CHAPTER 5: MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE

5.1.Overview

- 5.1.1.Market size and forecast

5.2.Conjugate Meningococcal Vaccines

- 5.2.1.Market size and forecast, by region
- 5.2.2.Market analysis, by country

5.3.Polysaccharide Vaccine

- 5.3.1.Market size and forecast, by region

- 5.3.2. Market analysis, by country
- 5.4. Subcapsular Vaccines
 - 5.4.1. Market size and forecast, by region
 - 5.4.2. Market analysis, by country

CHAPTER 6: MENINGOCOCCAL VACCINE MARKET, BY END USER

- 6.1. Overview
 - 6.1.1. Market size and forecast
- 6.2. Pediatrics
 - 6.2.1. Market size and forecast
 - 6.2.2. Market analysis, by country
- 6.3. Adults
 - 6.3.1. Market size and forecast
 - 6.3.2. Market analysis, by country
- 6.4. Traveler
 - 6.4.1. Market size and forecast
 - 6.4.2. Market analysis, by country

CHAPTER 7: MENINGOCOCCAL VACCINE MARKET BY REGION

- 7.1. Overview
 - 7.1.1. Market size and forecast
- 7.2. North America
 - 7.2.1. Key market trends, growth factors, and opportunities
 - 7.2.2. Market size and forecast, by country
 - 7.2.2.1. U.S.
 - 7.2.2.1.1. U.S. meningococcal vaccine market, by vaccine serotype
 - 7.2.2.1.2. U.S. meningococcal vaccine market, by vaccine type
 - 7.2.2.1.3. U.S. meningococcal vaccine market, by end user
 - 7.2.2.2. Canada
 - 7.2.2.2.1. Canada meningococcal vaccine market, by vaccine serotype
 - 7.2.2.2.2. Canada meningococcal vaccine market, by vaccine type
 - 7.2.2.2.3. Canada meningococcal vaccine market, by end user
 - 7.2.2.3. Mexico
 - 7.2.2.3.1. Mexico meningococcal vaccine market, by vaccine serotype
 - 7.2.2.3.2. Mexico meningococcal vaccine market, by vaccine type
 - 7.2.2.3.3. Mexico meningococcal vaccine market, by end user
 - 7.2.3. North America meningococcal vaccine market, by vaccine serotype

- 7.2.4.North America meningococcal vaccine market, by vaccine type
- 7.2.5.North America meningococcal vaccine market, by end user
- 7.3.Europe
 - 7.3.1.Key market trends, growth factors, and opportunities
 - 7.3.2.Market size and forecast, by country
 - 7.3.2.1.Germany
 - 7.3.2.1.1.Germany Meningococcal vaccines market, by Serotype
 - 7.3.2.1.2.Germany Meningococcal vaccines market, by Vaccine type
 - 7.3.2.1.3.Germany Meningococcal vaccines market, by end user
 - 7.3.2.2.France
 - 7.3.2.2.1.France Meningococcal vaccines market, by Serotype
 - 7.3.2.2.2.France Meningococcal vaccines market, by Vaccine type
 - 7.3.2.2.3.France Meningococcal vaccines market, by end user
 - 7.3.2.3.UK
 - 7.3.2.3.1.UK Meningococcal vaccines market, by Serotype
 - 7.3.2.3.2.UK Meningococcal vaccines market, by Vaccine type
 - 7.3.2.3.3.UK Meningococcal vaccines market, by end user
 - 7.3.2.4.The Netherlands
 - 7.3.2.4.1.The Netherlands Meningococcal vaccines market, by Serotype
 - 7.3.2.4.2.The Netherlands Meningococcal vaccines market, by Vaccine type
 - 7.3.2.4.3.The Netherlands Meningococcal vaccines market, by end user
 - 7.3.2.5.Spain
 - 7.3.2.5.1.Spain Meningococcal vaccines market, by Serotype
 - 7.3.2.5.2.Spain Meningococcal vaccines market, by Vaccine type
 - 7.3.2.5.3.Spain Meningococcal vaccines market, by end user
 - 7.3.2.6.Rest of Europe
 - 7.3.2.6.1.Rest of Europe Meningococcal vaccines market, by Serotype
 - 7.3.2.6.2.Rest of Europe Meningococcal vaccines market, by Vaccine type
 - 7.3.2.6.3.Rest of Europe Meningococcal vaccines market, by end user
 - 7.3.3.Europe Meningococcal vaccines market, by Serotype
 - 7.3.4.Europe Meningococcal vaccines market, by Vaccine type
 - 7.3.5.Europe Meningococcal vaccines market, by end user
- 7.4.Asia-Pacific
 - 7.4.1.Key market trends, growth factors, and opportunities
 - 7.4.2.Market size and forecast, by country
 - 7.4.2.1.China
 - 7.4.2.1.1.China meningococcal vaccine market, by vaccine serotype
 - 7.4.2.1.2.China meningococcal vaccine market, by vaccine type
 - 7.4.2.1.3.China meningococcal vaccine market, by end user

7.4.2.2.Australia

7.4.2.2.1.Australia meningococcal vaccine market, by vaccine serotype

7.4.2.2.2.Australia meningococcal vaccine market, by vaccine type

7.4.2.2.3.Australia meningococcal vaccine market, by end user

7.4.2.3.Rest of Asia-Pacific

7.4.2.3.1.Rest of Asia-Pacific meningococcal vaccine market, by vaccine serotype

7.4.2.3.2.Rest of Asia-Pacific meningococcal vaccine market, by vaccine type

7.4.2.3.3.Rest of Asia-Pacific meningococcal vaccine market, by end user

7.4.3.Asia-Pacific meningococcal vaccine market, by vaccine serotype

7.4.4.Asia-Pacific meningococcal vaccine market, by vaccine type

7.4.5.Asia-Pacific meningococcal vaccine market, by end user

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities

7.5.2.Market size and forecast, by country

7.5.2.1.Latin America

7.5.2.1.1.Latin America Meningococcal vaccines market, by Serotype

7.5.2.1.2.Latin America Meningococcal vaccines market, by Vaccine type

7.5.2.1.3.Latin America Meningococcal vaccines market, by end user

7.5.2.2.Middle East

7.5.2.2.1.Middle East Meningococcal vaccines market, by Serotype

7.5.2.2.2.Middle East Meningococcal vaccines market, by Vaccine type

7.5.2.2.3.Middle East Meningococcal vaccines market, by end user

7.5.2.3.Africa

7.5.2.3.1.Africa Meningococcal vaccines market, by Serotype

7.5.2.3.2.Africa meningococcal vaccines market, by vaccine type

7.5.2.3.3.Africa meningococcal vaccines market, by end user

7.5.3.LAMEA meningococcal vaccines market, by serotype

7.5.4.LAMEA meningococcal vaccines market, by vaccine type

7.5.5.LAMEA meningococcal vaccines market, by end user

CHAPTER 8:COMPANY PROFILES

8.1.Bio-Manguinhos

8.1.1.Company overview

8.1.2.Company snapshot

8.1.3.Operating business segments

8.1.4.Product portfolio

8.2.Bio-Med Pvt. Limited

8.2.1.Company overview

- 8.2.2. Company snapshot
- 8.2.3. Operating business segments
- 8.2.4. Product portfolio
- 8.3. Chongqing Zhifei Biological Products Co., Ltd.
 - 8.3.1. Company overview
 - 8.3.2. Company snapshot
 - 8.3.3. Operating business segments
 - 8.3.4. Product portfolio
- 8.4. GlaxoSmithKline Plc
 - 8.4.1. Company overview
 - 8.4.2. Company snapshot
 - 8.4.3. Operating business segments
 - 8.4.4. Product portfolio
 - 8.4.5. Business performance
 - 8.4.1. Key strategic moves and developments
- 8.5. Hualan Biological Engineering Inc.
 - 8.5.1. Company overview
 - 8.5.2. Company snapshot
 - 8.5.3. Operating business segments
 - 8.5.4. Product portfolio
- 8.6. Incepta Pharmaceuticals Ltd.
 - 8.6.1. Company overview
 - 8.6.2. Company snapshot
 - 8.6.3. Operating business segments
 - 8.6.4. Product portfolio
- 8.7. PFIZER INC.
 - 8.7.1. Company overview
 - 8.7.2. Company snapshot
 - 8.7.3. Operating business segments
 - 8.7.4. Product portfolio
 - 8.7.5. Business performance
- 8.8. SANOFI S.A.
 - 8.8.1. Company overview
 - 8.8.2. Company snapshot
 - 8.8.3. Operating business segments
 - 8.8.4. Product portfolio
 - 8.8.5. Business performance
- 8.9. SERUM INSTITUTE OF INDIA PVT. LTD
 - 8.9.1. Company overview

8.9.2. Company snapshot

8.9.3. Operating business segments

8.9.4. Product portfolio

8.10. Walvax Biotechnology Co., Ltd.

8.10.1. Company overview

8.10.2. Company snapshot

8.10.3. Operating business segments

8.10.4. Product portfolio

List Of Tables

LIST OF TABLES

TABLE 01.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY VACCINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 02.MENACWY VACCINE MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 03.MENINGOCOCCAL VACCINE MARKET FOR MENB AND BC VACCINE MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 04.MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 05.MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 06.MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 07.GLOBAL MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 08.COMPETITIVE CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 09.POLYSACCHARIDE MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 10.SUBCAPSULAR MENINGOCOCCAL VACCINES MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 11.GLOBAL MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 12.MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, BY REGION, 2018–2026 (\$MILLION)

TABLE 13.MENINGOCOCCAL VACCINES MARKET FOR ADULTS, BY REGION, 2018–2026 (\$MILLION)

TABLE 14.MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, BY REGION, 2018–2026 (\$MILLION)

TABLE 15.MENINGOCOCCAL VACCINE MARKET, BY REGION, 2018–2026 (\$MILLION)

TABLE 16.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 17.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 18.U.S. MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 19.U.S. MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 20.CANADA MENINGOCOCCAL VACCINE MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 21.CANADA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 22.CANADA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 23.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 24.MEXICO MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 25.MEXICO MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 26.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 27.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 28.NORTH AMERICA MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 29.EUROPE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 30.GERMANY MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 31.GERMANY MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 32.GERMANY MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 33.FRANCE MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 34.FRANCE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 35.FRANCE MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 36.UK MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 37.UK MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 38.UK MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026

(\$MILLION)

TABLE 39.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY
SERO TYPE, 2018–2026 (\$MILLION)TABLE 40.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY
VACCINE TYPE, 2018–2026 (\$MILLION)TABLE 41.THE NETHERLANDS MENINGOCOCCAL VACCINES MARKET, BY END
USER, 2018–2026 (\$MILLION)TABLE 42.SPAIN MENINGOCOCCAL VACCINES MARKET, BY SERO TYPE,
2018–2026 (\$MILLION)TABLE 43.SPAIN MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE,
2018–2026 (\$MILLION)TABLE 44.SPAIN MENINGOCOCCAL VACCINES MARKET, BY END USER,
2018–2026 (\$MILLION)TABLE 45.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY
SERO TYPE, 2018–2026 (\$MILLION)TABLE 46.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY
VACCINE TYPE, 2018–2026 (\$MILLION)TABLE 47.REST OF EUROPE MENINGOCOCCAL VACCINES MARKET, BY END
USER, 2018–2026 (\$MILLION)TABLE 48.EUROPE MENINGOCOCCAL VACCINES MARKET, BY SERO TYPE,
2018–2026 (\$MILLION)TABLE 49.EUROPE MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE,
2018–2026 (\$MILLION)TABLE 50.EUROPE MENINGOCOCCAL VACCINES MARKET, BY END USER,
2018–2026 (\$MILLION)TABLE 51.ASIA- PACIFIC MENINGOCOCCAL VACCINE MARKET, BY COUNTRY,
2018–2026 (\$MILLION)TABLE 52.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE SERO TYPE,
2018–2026 (\$MILLION)TABLE 53.CHINA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE,
2018–2026 (\$MILLION)TABLE 54.CHINA MENINGOCOCCAL VACCINE MARKET, BY END USER,
2018–2026 (\$MILLION)TABLE 55.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE
SERO TYPE, 2018–2026 (\$MILLION)TABLE 56.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE,
2018–2026 (\$MILLION)TABLE 57.AUSTRALIA MENINGOCOCCAL VACCINE MARKET, BY END USER,
2018–2026 (\$MILLION)

TABLE 58.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 59.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 60.REST OF ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 61.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACINE SEROTYPE, 2018–2026 (\$MILLION)

TABLE 62.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 63.ASIA-PACIFIC MENINGOCOCCAL VACCINE MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 64.LAMEA MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018–2026 (\$MILLION)

TABLE 65.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 66.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 67.LATIN AMERICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 68.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 69.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 70.MIDDLE EAST MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 71.AFRICA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 72.AFRICA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 73.AFRICA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 74.LAMEA MENINGOCOCCAL VACCINES MARKET, BY SEROTYPE, 2018–2026 (\$MILLION)

TABLE 75.LAMEA MENINGOCOCCAL VACCINES MARKET, BY VACCINE TYPE, 2018–2026 (\$MILLION)

TABLE 76.LAMEA MENINGOCOCCAL VACCINES MARKET, BY END USER, 2018–2026 (\$MILLION)

TABLE 77.BIO-MANGUINHOS: COMPANY SNAPSHOT

TABLE 78.BIO-MANGUINHOS: OPERATING SEGMENTS

TABLE 79.BIO-MANGUINHOS: PRODUCT PORTFOLIO

TABLE 80.BIO-MED: COMPANY SNAPSHOT

TABLE 81.BIO-MED: OPERATING SEGMENTS

TABLE 82.BIO-MED: PRODUCT PORTFOLIO

TABLE 83.ZHIFEI: COMPANY SNAPSHOT

TABLE 84.ZHIFEI: PRODUCT SEGMENTS

TABLE 85.ZHIFEI: PRODUCT PORTFOLIO

TABLE 86.GSK: COMPANY SNAPSHOT

TABLE 87.GSK: OPERATING SEGMENTS

TABLE 88.GSK: PRODUCT PORTFOLIO

TABLE 89.HUALAN BIO: COMPANY SNAPSHOT

TABLE 90.HUALAN BIO: OPERATING SEGMENTS

TABLE 91.HUALAN BIO: PRODUCT PORTFOLIO:

TABLE 92.INCEPTA: COMPANY SNAPSHOT

TABLE 93.INCEPTA: OPERATING SEGMENTS

TABLE 94.INCEPTA: PRODUCT PORTFOLIO

TABLE 95.PFIZER: COMPANY SNAPSHOT

TABLE 96.PFIZER: OPERATING SEGMENTS

TABLE 97.PFIZER: PRODUCT PORTFOLIO

TABLE 98.SANOFI: COMPANY SNAPSHOT

TABLE 99.SANOFI: OPERATING SEGMENTS

TABLE 100.SANOFI: PRODUCT PORTFOLIO:

TABLE 101.SERUM INSTITUTE.: COMPANY SNAPSHOT

TABLE 102.SERUM INSTITUTE: PRODUCT PORTFOLIO

TABLE 103.WALVAX: COMPANY SNAPSHOT

TABLE 104.WALVAX: OPERATING SEGMENTS

TABLE 105.WALVAX: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

FIGURE 01.MENINGOCOCCAL VACCINE MARKET SEGMENTATION

FIGURE 02.TOP INVESTMENT POCKETS IN THE GLOBAL MENINGOCOCCAL VACCINE MARKET, 2018

FIGURE 03.MODERATE BARGAINING POWER OF BUYERS

FIGURE 04.MODERATE BARGAINING POWER OF SUPPLIERS

FIGURE 05.MODERATE THREAT OF NEW ENTRANTS

FIGURE 06.HIGH COMPETITIVE RIVALRY

FIGURE 07.MARKET SHARE ANALYSIS, 2018

FIGURE 08.IMPACT ANALYSIS

FIGURE 09.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET, BY COUNTRY, 2018 & 2026, BY VALUE

FIGURE 10.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENB MARKET, BY COUNTRY, 2018 & 2026, BY VALUE

FIGURE 11.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENC MARKET, BY COUNTRY, 2018 & 2026, BY VALUE

FIGURE 12.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENA VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE

FIGURE 13.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINE MARKET FOR MENAC VACCINE MARKET, BY COUNTRY, 2018 & 2026 BY VALUE

FIGURE 14.COMPARATIVE ANALYSIS OF CONJUGATE MENINGOCOCCAL VACCINES MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE

FIGURE 15.COMPARATIVE ANALYSIS OF POLYSACCHARIDE VACCINE MARKET, BY COUNTRY, 2018 & 2026 (%), BY VALUE

FIGURE 16.COMPARATIVE ANALYSIS OF SUBCAPSULAR MENINGOCOCCAL VACCINE, BY COUNTRY, 2018 & 2026 (%), BY VALUE

FIGURE 17.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR PEDIATRICS, 2018 & 2026, (\$MILLION)

FIGURE 18.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR ADULTS, 2018 & 2026, (\$MILLION)

FIGURE 19.COMPARATIVE ANALYSIS OF MENINGOCOCCAL VACCINES MARKET FOR TRAVELLERS, 2018 & 2026, (\$MILLION)

FIGURE 20.GSK: NET SALES, 2017–2018 (\$MILLION)

FIGURE 21.GSK REVENUE SHARE BY SEGMENTS, 2018 (%)

FIGURE 22.GSK: REVENUE SHARE BY REGIONS, 2018 (%)

FIGURE 23.NET SALES, 2016–2018 (\$MILLION)

FIGURE 24.PFIZER: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 25.PFIZER: REVENUE SHARE BY REGION, 2018 (%)

FIGURE 26.SANOFI: NET SALES, 2016–2018 (\$MILLION)

FIGURE 27.SANOFI: REVENUE SHARE BY SEGMENT, 2018 (%)

FIGURE 28.SANOFI: REVENUE SHARE BY REGION, 2018 (%)

I would like to order

Product name: Meningococcal Vaccine Market by Serogroup (MenACWY, MenB/BC, MenC, MenAC, and MenA), Vaccine Type (Conjugate, Polysaccharide, and Subcapsular), and End User (Pediatric, Adults, and Travelers): Global Opportunity Analysis and Industry Forecast, 2018–2026

Product link: <https://marketpublishers.com/r/MEB902A68453EN.html>

Price: US\$ 4,296.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MEB902A68453EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970